Baby Safety / Compounds / Ketamine

Is Ketamine safe for babies and kids?

Moderate risk for kids

Infants are more vulnerable to Ketamine than children or adults due to immature hepatic/renal clearance, higher intake-to-body-weight ratio, rapid organ development, and increased gastrointestinal absorption.

What is ketamine?

The IUPAC name is 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one.

Also known as: 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one, dl-Ketamine, Ketaject, Special K.

IUPAC name
2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
CAS number
6740-88-1
Molecular formula
C13H16ClNO
Molecular weight
237.72 g/mol
SMILES
CNC1(CCCCC1=O)C2=CC=CC=C2Cl
PubChem CID
3821

Risk for babies

Moderate risk

Infants are more vulnerable to Ketamine than children or adults due to immature hepatic/renal clearance, higher intake-to-body-weight ratio, rapid organ development, and increased gastrointestinal absorption.

Neonates and infants up to 12 months have incomplete blood-brain barrier development, immature Phase I/II metabolic enzymes (particularly CYP3A4, UGT1A1), and higher gastrointestinal permeability. Equivalent doses produce higher internal concentrations and longer residence times.

What to do: Minimize infant exposure through source control. For breastfeeding mothers: reduce maternal exposure. For formula-fed infants: use certified low-migration bottles and verified water sources. Consult pediatrician regarding any concerns.

Risk for pregnant and nursing people

Context-dependent

Pregnancy alters the metabolism and distribution of Ketamine, potentially increasing fetal exposure. The developing embryo/fetus is vulnerable during organogenesis (weeks 3-8) and neurological development. Placental transfer should be assumed.

No specific reproductive toxicity data identified, but pregnancy-specific safety data is limited for most chemicals. Precautionary minimization of exposure is recommended.

What to do: Minimize exposure during pregnancy and lactation. Consult healthcare provider regarding specific risks. Consider alternative products with lower hazard profiles.

Regulatory consensus

1 regulatory bodyhas classified Ketamine.

AgencyYearClassificationNotes
DEA—Schedule IIIUnited States Drug Enforcement Administration scheduling

Regulators apply different standards of evidence — animal-data weighting, exposure-pattern assumptions, epidemiological power thresholds — which is why two scientific bodies can review the same data and reach different conclusions. The disagreement is the data.

Where kids encounter ketamine

  • Industrial Facilities — Manufacturing plants, Chemical storage areas, Waste treatment sites
  • Occupational Environments — Factories, Warehouses, Transportation vehicles

Safer alternatives

Lower-risk approaches that achieve a similar outcome to Ketamine:

  • Therapeutic alternatives (consult prescriber)
    Trade-offs: Drug-specific. Cannot substitute without medical guidance.
    Relative cost: 1.2-2×

Frequently asked questions

Is ketamine safe for kids?

Infants are more vulnerable to Ketamine than children or adults due to immature hepatic/renal clearance, higher intake-to-body-weight ratio, rapid organ development, and increased gastrointestinal absorption.

What products contain ketamine?

Ketamine appears in: Manufacturing plants (Industrial facilities); Chemical storage areas (Industrial facilities); Factories (Occupational environments); Warehouses (Occupational environments).

What should I do if my child is exposed to ketamine?

Minimize infant exposure through source control. For breastfeeding mothers: reduce maternal exposure. For formula-fed infants: use certified low-migration bottles and verified water sources. Consult pediatrician regarding any concerns.

See Ketamine in the baby app

Look up products containing ketamine, compare to alternatives, and explore the full data record.

Open in baby View raw API data

Sources (2)
  1. US DEA: Ketamine — Schedule III Controlled Substance, Veterinary and Medical Anesthesia Uses, Ketamine-Induced Uropathy Epidemiology, Recreational Misuse Trends, and Hepatotoxicity Reports (2022) (2022) — regulatory
  2. US FDA: Esketamine (Spravato) — Approval for Treatment-Resistant Depression (2019), Pediatric Brain Development Advisory (2016, General Anesthetic Agents in Children <3 Years), REMS Program, and Ketamine Compounding for Depression (2023) (2023) — regulatory

Reference data, not professional advice. Aggregates publicly available regulatory and scientific data; not a substitute for veterinary, medical, legal, or regulatory advice. Why we built ALETHEIA →